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The slow-channel myasthenic syndrome (SCS) is a hereditary disorder of the acetylcholine receptor (AChR)
of the neuromuscular junction (NMJ) that leads to prolonged AChR channel opening, Ca2+ overload, and
degeneration of the NMJ. We used an SCS transgenic mouse model to investigate the role of the calcium-activated protease calpain in the pathogenesis of synaptic dysfunction in SCS. Cleavage of a fluorogenic calpain
substrate was increased at the NMJ of dissociated muscle fibers. Inhibition of calpain using a calpastatin (CS)
transgene improved strength and neuromuscular transmission. CS caused a 2-fold increase in the frequency of
miniature endplate currents (MEPCs) and an increase in NMJ size, but MEPC amplitudes remained reduced.
Persistent degeneration of the NMJ was associated with localized activation of the non-calpain protease
caspase-3. This study suggests that calpain may act presynaptically to impair NMJ function in SCS but further
reveals a role for other cysteine proteases whose inhibition may be of additional therapeutic benefit in SCS
and other excitotoxic disorders.
*OUSPEVDUJPO
The slow-channel congenital myasthenic syndrome (SCS) is a dominantly inherited neuromuscular disorder characterized by impaired
neuromuscular transmission and degeneration of the neuromuscular junction (NMJ) (1–3). Patients with SCS manifest fatigability
and progressive weakness of the skeletal muscles, with symptoms
ranging from eye muscle and mild limb weakness to severe incapacitation and respiratory failure. Ultrastructural study of muscle
in SCS reveals a focal degenerative and remodeling process selectively localized to the NMJ termed endplate myopathy. This progressive, purely synaptic disease process, in which the cleft is widened
and nerve terminals are shrunken, is characterized by expansion
and degeneration of postsynaptic folds as well as degeneration of
subsynaptic nuclei, mitochondria, and myofibrils (1–4).
The SCS is caused by missense mutations within the genes
encoding nicotinic acetylcholine receptor (AChR) subunits. The
mutations alter the AChR channel gating function, causing prolonged activation events, persistent synaptic currents, and localized calcium overload at the NMJ, amplified by calcium release
from intracellular stores (1, 3, 5–10). These changes lead to weakness and impaired neuromuscular transmission through an effect
on both pre- and postsynaptic determinants of synaptic transmission, including quantal release, synaptic cleft anatomy, and the
Nonstandard abbreviations used: AChR, nicotinic acetylcholine receptor;
BOC-Leu-Met-CMAC, t-butoxycarbonyl-Leu-Met-7-amino-4-chloromethyl-coumarin;
αBT, α-bungarotoxin; CMAP, compound muscle action potential; CP1, calpain inhibitor 1; CS, calpastatin; FDB, flexor digitorum brevis; GBHA, glyoxal-bis-2-hydroxyanil;
MEPC, miniature endplate current; NMJ, neuromuscular junction; RαBT, αBT conjugated to Texas red; SCS, slow-channel congenital myasthenic syndrome;
SR-VAD-FMK, sulforhodamine-labeled VAD-FMK.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 117:2903–2912 (2007). doi:10.1172/JCI30383.
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function and density of postsynaptic AChRs. Expression of several distinct AChR mutations characteristic of the SCS in transgenic mice reproduces the features of the SCS. The SCS mutation,
εL269F, expressed in transgenic mice, most closely reproduces the
clinical syndrome of weakness, fatigability, and impaired neuromuscular transmission (9, 10).
Elucidating the biochemical pathways coupling the ionic disturbance in SCS to the synaptic degeneration may be of benefit to
understanding other degenerative disorders of nerve and muscle.
Activation of endogenous proteolytic enzymes plays a prominent
role in cell death, in muscular dystrophy, and in neurodegenerative
diseases (11–13). We previously showed that some forms of the cysteine proteases, caspases that play a prominent role in the apoptotic cascade, are locally activated at the NMJ in SCS and in its transgenic mouse model (14, 15). Calcium overload of muscle fibers that
is highly localized to the NMJ in SCS might exhaust calcium buffering reserves and activate the calcium-activated cysteine protease
calpain. Previous attempts to detect activated calpain polypeptide
in Western blots in SCS muscle homogenates were unsuccessful,
perhaps due to the localized nature of the process. In this study we
employed the enzymatic substrate, t-butoxycarbonyl-Leu-Met-7amino-4-chloromethyl-coumarin (BOC-Leu-Met-CMAC), a fluorogenic calpain substrate used to detect calpain-like activity within
living cells. The nonfluorescent BOC-Leu-Met-CMAC molecule is
membrane permeable and becomes nondiffusible by enzymatic
conjugation to thiol groups by glutathione-S-transferase (16). Proteolytic cleavage at the methionine residue releases and unquenches
the fluorescent membrane-insoluble MAC-thiol moiety.
We investigated the role of calpain in impaired synaptic transmission seen in SCS. We found that calpain activity in muscle
fibers from εL269F SCS transgenic mice was significantly elevated
at the NMJ, was dependent on synaptic activity, and diminished
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to baseline with AChR blockade. Transgenic expression of human
calpastatin (CS), the natural inhibitor of calpain, in εL269F mice
reduced calpain to baseline, normalized NMJ size and miniature
endplate current (MEPC) frequency and improved strength and
neuromuscular transmission. Persistent endplate myopathy in
CS-SCS double transgenic mice was associated with ongoing, localized activation of components of the caspase family of cysteine
proteases, which are not inhibited by CS. These findings provide
evidence for the role of 2 separate families of cysteine proteases in
the SCS, for which separate therapeutic strategies for inhibition
may provide synergistic benefit.
3FTVMUT
Muscle calpain activity is elevated in a transgenic model of SCS. Using
dissociated muscle fibers from the flexor digitorum brevis (FDB)
loaded with the fluorogenic calpain substrate BOC-Leu-MetCMAC, we compared the fluorescent signal from SCS and control
fibers taken from mice aged 4–8 months. Many FDB fibers from
εL269F mice had visibly elevated fluorescence, some with regions
suggesting intense calpain activity localized to endplate areas (Figure 1A), while nontransgenic control fibers (WT) had less intense
fluorescence (Figure 1B). The mean fluorescence signal intensity of εL269F SCS fibers at endplates was approximately 2-fold
greater than that of WT fibers (Figure 1C; 1,591 ± 72 vs. 815 ± 72;
n = 10; P < 0.01). We confirmed the specificity of these signals by
preincubation with vehicle or with a specific peptide inhibitor of
calpain, calpain inhibitor 1 (CP1). CP1 treatment of εL269F fibers
led to a significant reduction in calpain activity when compared
with untreated εL269F fibers (801.6 ± 25; n = 3; P < 0.01). The fluorescence signal of CP1-treated εL269F fibers was similar to that
of untreated WT (815.1 ± 72; n = 10; P = 0.86), vehicle-treated WT
(855.3 ± 52; n = 3; P = 0.66), or CP1-treated WT fibers (924 ± 34;
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n = 3; P = 0.27). Pretreatment of εL269F SCS fibers with vehicle had
no effect on calpain activity (vehicle: 1,593 ± 72, n = 3, vs. untreated:
1,591 ± 72, n = 10; P = 0.99). These findings indicate that muscle
fibers from transgenic mice expressing εL269F AChRs have elevated
calpain activity, particularly in the region of the NMJ.
Calpain activity in slow-channel mouse endplates requires active synapses. Previous studies have shown that Ca2+ accumulates to
histochemically detectable levels at NMJs in human SCS and in
εL269F SCS mice and increases within minutes after neuromuscular activity, in part due to release from internal stores (1, 10,
15, 17). Figure 2A shows that these focal Ca2+ accumulations are
also dependent on intact muscle innervation. The number of endplates with accumulations detectable by glyoxal-bis-2-hydroxyanil
(GBHA) stain was reduced 3-fold by 24 hours after axotomy, from
47% ± 6.2% to 15% ± 1.3% (P < 0.01; n = 3) and was undetectable
after 48 hours. Because of the rapid disappearance of the deposits
of endplate Ca2+ after axotomy, we tested whether calpain activity in SCS muscle was similarly dependent on muscle innervation.
Surgical axotomy significantly reduced calpain activity of εL269F
FDB fibers (Figure 2B; 761 ± 78) by 24 hours but had no effect
on the contralateral, innervated FDB fibers (1,447 ± 73; n = 3;
P < 0.01). To insure that axotomy did not activate calpain through
cell-signaling events caused by nerve retraction or trophic factor
withdrawal from muscle fibers, we tested the effect of irreversible
blockade of AChR activation using α-bungarotoxin (αBT) (18). In
preliminary experiments we established the dose of αBT needed
to completely block AChRs in the FDB muscle. As with axotomy,
complete blockade of AChRs in vivo caused a significant reduction
in calpain activity assessed after 24 hours when compared with
the untreated contralateral hind limb (Figure 2C; 1,009 ± 84 vs.
1,600 ± 98; n = 4; P < 0.01). Therefore, increased calpain activation
in SCS requires continuous activation of mutant AChRs.
A CS transgene normalizes calpain activity in double-transgenic εL269F
muscle. We hypothesized that increased calpain activity in SCS
may contribute to the pathogenesis of the SCS. To test the protective effect of CS in SCS, we bred εL269F mice with mice bearing a
human CS transgene targeted to skeletal muscle (CS mice) to generate mice bearing both the SCS and CS transgenes (CS/εL269F
mice). Transgenic overexpression of CS in mdx mice improved
dystrophic changes (19). We found that, as with incubation with
CP1, CS reduced the level of calpain activation in εL269F mice
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to baseline levels. Figure 3 compares the BOC-Leu-Met-CMAC
fluorescence signal from muscle fibers of εL269F (Figure 3A),
CS/εL269F (Figure 3B), control CS (Figure 3C), and WT mice
(Figure 3D). Analysis of fluorescence intensity at muscle fiber endplate regions (Figure 3E) revealed that the increased calpain activity in εL269F muscle fibers was significantly reduced by the presence of the CS transgene (1,607 ± 79, n = 9, vs. 990.0 ± 145; n = 5;
P < 0.05) and that calpain activity of CS (1,029 ± 83; n = 5) and
control (WT, 819.0 ± 92; n = 8) was similar in the populations of
fibers (P = 0.83 and P = 0.34, respectively) when compared with
CS/εL269F. Finally, to validate the specificity and consequences
of the measured changes in calpain activity with respect to
known calpain substrates, we used immunoblotting with antibodies for specific calpain substrates. Figure 3F shows results of
an immunoblot for troponin-I, a calpain substrate, using muscle
homogenates that suggests that the 24-kDa troponin-specific
species is reduced in muscle from εL269F mice compared with
both WT and CS/εL269F mice. Last, to ensure that the expression of the CS transgene was unchanged by coexpression of the
εL269F transgene, we compared CS levels in WT, CS single-transgenic, εL269F single-transgenic, and CS/εL269F double-transgenic muscle by immunoblotting with anti-CS antibody. Figure
3G demonstrates that the expression of the human CS transgene
greatly exceeded that of endogenous mouse CS but was unaltered
by coexpression of the εL269F transgene. These results provide
qualitative evidence to support the conclusion of the fluorogenic
substrate study that calpain activity is increased in εL269F muscle
and normalized in CS/εL269F muscle.
CS improves strength in εL269F transgenic mice. To investigate whether chronic inhibition of calpain activity improved the clinical picture of SCS, we compared the strength of CS/εL269F mice with
that of εL269F mice that did not bear the additional CS transgene
using a grip strength paradigm (Figure 4) (9). Mice bearing the CS
transgene alone behaved identically to WT mice both in open cage
observation and in their performance in the grip strength experiment. As shown previously, transgenic εL269F had significantly
less grip strength when compared with nontransgenic (WT) littermates (16 ± 5, n = 8, vs. 97 ± 1, n = 5; P < 0.05) (9). CS/εL269F
The Journal of Clinical Investigation

double-transgenic mice had significantly improved grip strength
when compared with εL269F littermates (67 ± 8, n = 9, vs. 16 ± 5,
n = 8; P < 0.05), although it was not fully corrected to normal.
CS overexpression improves neuromuscular transmission in εL269F
mice. To investigate the physiological basis for the improvement in
strength in εL269F mice conferred by coexpression of the CS transgene, we recorded electromyographic responses to repetitive nerve
stimulation. As described previously, εL269F (Figure 5A) mice
exhibited compound muscle action potentials (CMAPs) that were
successively decreasing in amplitude (decremental responses) when
evoked by repetitive stimulation at 10 Hz, a hallmark of impaired
neuromuscular transmission (20). CS/εL269F mice (Figure 5B) had
significantly smaller decremental responses when compared with
εL269F mice (Figure 5E; 9.0 ± 1.3 vs. 17 ± 3.2; n = 8; P < 0.05). When
compared with each other, neither CS mice nor nontransgenic
control mice had significant decremental responses (Figure 5, C–E;
3.6 ± 1.2, n = 6, vs. 3.4 ± 0.75, n = 7; P = 0.94). Thus, consistent
with its effect on strength in εL269F mice, the CS transgene partially corrected the impaired neuromuscular transmission seen in
εL269F slow-channel transgenic mice.
The expression of CS corrects MEPC frequencies. Impaired synaptic
function in SCS is due to a combination of effects of the mutant
AChR on the pre- and postsynaptic determinants of successful
neuromuscular transmission. To investigate the electrophysiological basis for the improved neuromuscular transmission caused by
inhibition of calpain in SCS mice, we evaluated synaptic function
by 2-electrode voltage-clamp analysis. This in vitro technique allows
recording of spontaneous MEPCs in excised diaphragm muscle. Figure 6, A–D, shows representative recordings of MEPCs from εL269F
mice (Figure 6A), CS/εL269F mice (Figure 6B), CS mice bearing the
CS transgene alone (Figure 6C, CS), and nontransgenic littermates
(Figure 6D, WT). MEPC recordings from each genotype were analyzed with respect to 3 parameters: MEPC decay rate (Figure 6E),
MEPC amplitude (Figure 6F), and MEPC frequency (Figure 6G).
The MEPC is the reflection of the opening of the AChR channels induced by quantal release of ACh. It has an exponential
decay phase whose rate can be defined by the time constant (τ)
of this exponential decay function, which, in turn is proportional

http://www.jci.org

Volume 117

Number 10

October 2007



Downloaded on August 12, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/30383

SFTFBSDIBSUJDMF
'JHVSF
5SBOTHFOJD$4PWFSFYQSFTTJPOOPSNBMJ[FTDBMQBJOBDUJWJUZJOEPVCMF
USBOTHFOJDε-''%#GJCFST "m% 3FQSFTFOUBUJWFJNBHFTPG'%#
NVTDMFGJCFSTGSPNε-' " $4ε-' # $4 $ BOEOPOUSBOT
HFOJD 85NJDF %  " ε-'NVTDMFGJCFSTPDDBTJPOBMMZSFWFBMFE
JOUFOTFSFHJPOTPGDBMQBJOBDUJWJUZOFBSPSDPMPDBMJ[FEUPUIF/.+
JOTFU ×UPPSJHJOBM  & $BMQBJOBDUJWJUZXBTTJHOJGJDBOUMZSFEVDFE
JO$4ε-'EPVCMFUSBOTHFOJDNJDFDPNQBSFEXJUIε-'NJDF
 O WT  O1 5IJTSFEVDUJPO
XBTTJNJMBSUPMFWFMTPCTFSWFEJO$4  O BOE85NJDF
O1 /PTJHOJGJDBOUEJGGFSFODFXBTPCTFSWFE
XIFO$4ε-' $4 BOE85NJDFXFSFDPNQBSFE 1  ' 
8FTUFSOCMPUPG'%#NVTDMFIPNPHFOBUFTQSPCFEXJUIUSPQPOJO*
5SPQ*L%B BOUJTFSBXJUIMPBEJOHDPOUSPM *H(IFBWZDIBJO 
L%B JMMVTUSBUJOHQSPUFDUJPOPGGVMMMFOHUIUSPQPOJO*JO$4ε-'
NJDF ( 6QQFSQBOFM $4NVTDMFIPNPHFOBUFT NJDFGPSFBDI
HFOPUZQF QSPCFEXJUINPOPDMPOBMBOUJ$4BOUJCPEZEFNPOTUSBUJOH
UIBUUIFTUSPOHTJHOBMGPSUSBOTHFOJDIVNBO$4DPNQBSFEXJUINPVTF
$4JTOPUBGGFDUFECZDPFYQSFTTJPOPGUIFε-'USBOTHFOF-PXFS
QBOFM -$1PODFBVSFETUBJOJOHTIPXJOHBDUJOCBOEGPSMPBEJOHDPO
USPM4DBMFCBSμN

to the mean duration of the opening events for the AChR channels (21). Although not directly responsible for the impairment
in neuromuscular transmission in SCS, prolonged decay phases
(increased MEPCτ) due to point mutations in the AChR subunits
that slow the closure of the channel are a hallmark of this disease.
MEPC decay phase analysis is depicted in Figure 6E. The decay
phase, MEPCτ, for εL269F mice (9.83 ± 0.98; n = 27) was significantly prolonged compared with that for WT (2.51 ± 0.15; n = 24)
and CS mice (2.82 ± 0.14; n = 24), consistent with previous studies
reflecting predominant expression of the εL269F mutant AChR
subunit over WT ε AChR subunit. The MEPCτ for CS/εL269F
mice (8.29 ± 0.75; n = 34) was similarly prolonged compared with
that for control mice (P < 0.05), reflecting the same preponderance of mutant AChRs.
As shown previously, MEPC amplitudes of εL269F mice were
diminished when compared with those of nontransgenic littermates (Figure 6F; 1.61 ± 0.12 nA, n = 26, vs. 2.20 ± 0.10 nA,
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n = 31; P < 0.05), a change attributed to the combined effects of the
disrupted synaptic architecture and the reduced number of endplate AChRs (1, 9). MEPC amplitudes (Figure 6F; 1.39 ± 0.03 nA,
n = 71, vs. 1.61 ± 0.12 nA, n = 26; P = 0.04) were slightly smaller in
CS/εL269F mice compared with εL269F mice, although the difference did not reach significance. However, the trend toward reduced
MEPC amplitudes associated with the CS transgene contrasts with
the improved synaptic function in CS/εL269F mice and implies
that a presynaptic, positive effect on synaptic function prevails.
The frequency of spontaneous quantal release of MEPCs in
εL269F mice was severely diminished when compared with that
in nontransgenic littermates (Figure 6G; 0.29 ± 0.02 s–1, n = 23, vs.
0.57 ± 0.02 s–1, n = 57; P < 0.05). This presynaptic change, also seen
in some SCS patients (1, 2), can be attributed to the severe remodeling and disruption in endplate architecture in SCS and likely
contributes significantly to impaired neuromuscular transmission
through reduced quantal content and reduced amplitude of the
evoked endplate potentials. In CS/εL269F mouse diaphragm, the
MEPC frequency was increased by approximately 2-fold compared
with that in εL269F mice (Figure 6G; 0.51 ± 0.06 s–1, n = 22, vs.
0.29 ± 0.02 s–1, n = 23) and similar to that in normal mice. MEPC
frequency was also approximately doubled in CS mice when compared with that in nontransgenic mice (1.17 ± 0.17 s–1, n = 14, vs.
0.57 ± 0.02 s–1, n = 57 NMJs; P < 0.05). Increased MEPC frequency
in muscle from mice overexpressing a calpain inhibitor in muscle is consistent with the demonstrated role of calpain and other
proteases in synaptic withdrawal, based on the effect of calpain
inhibitors in stabilizing synaptic contacts (22–25).
Molecular and structural correlates for improved strength and neuromuscular transmission in SCS. Reduced MEPC amplitudes in SCS and
other NMJ disorders are attributed, in part, to a reduced number
of AChRs at the NMJ. We previously demonstrated that endplate
AChRs are reduced in εL269F SCS mice by determining the number of AChRs per endplate in teased brachioradialis fibers using
[125I]αBT (10). This presumably results from the severe degenerative changes (endplate myopathy) exhibited by these mice. Endplate AChRs in CS/εL269F double-transgenic mice were slightly
reduced but not significantly different from those in εL269F transgenic mice in this assay (εL269F: 2.65 ± 0.03 pmol vs. CS/εL269F:
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2.22 ± 0.03 pmol; n = 8; P = 0.3). Although additional studies may
be needed to confirm the reduced AChR number, the trend is consistent with the observed trend toward reduced MEPC amplitudes
in CS/εL269F mice compared with εL269F mice.
We investigated the structural basis for the improved MEPC frequency, which had a greater impact on synaptic function than did
the slight change in MEPC amplitudes. Using αBT conjugated
to Texas red (RαBT) to label endplates in dissociated FDB fibers
(4 animals/group), we measured the mean size (in μm2) of the endplate regions in εL269F, CS/εL269F, CS, and nontransgenic littermates (WT; Figure 7). As noted in SCS patient biopsies, mean endplate size in SCS transgenic mice was significantly reduced when
compared to that in nontransgenic littermates (33 ± 1.9 μm2,
n = 248, vs. 87 ± 4.8 μm2, n = 121; P < 0.05). In contrast, endplate
size in CS/εL269F mice was significantly increased, by approximately 2-fold, compared with that in εL269F mice (62 ± 5.4 μm2,
n = 139, vs. 33 ± 1.9 μm2, n = 248 fibers; P < 0.05), although it
was not fully corrected to normal. These morphological findings
are consistent with the action of calpain inhibitors in reducing
endplate remodeling and stabilizing neuromuscular contacts
and correlate with the improved MEPC frequency in CS/εL269F
mice. Curiously, although the CS mice also had increased MEPC
frequency compared with WT, CS endplates were not larger than
normal, suggesting that, as noted in other studies (22–25), calpain
inhibition acts presynaptically to increase synaptic contacts.
To investigate the effect of the CS transgene on the endplate
myopathy, we compared electron micrographs of NMJs from
εL269F transgenic mice (Figure 8A) with those of CS/εL269F
double-transgenic mice (Figure 8B). Several features of the endplate myopathy were qualitatively similar in both groups. Specifically, degenerating nuclei, mitochondria, granular debris in the
cleft, and vacuoles appeared to be present in equal abundance.
However, in the subjunctional area of the εL269F muscle fibers,
the myofibrils appeared to be more consistently disorganized and
the Z bands focally blurred (Figure 8A, arrowhead), a change also
seen in muscle biopsies of SCS patients. To assess this finding,

we encoded the identity of the electron micrographs and scored
them anonymously for presence or absence of this pattern of focal
myofibrillar degeneration (Figure 8D). We found that 86% ± 7%
of εL269F endplates had focal myofibrillar abnormalities, compared with only 30% ± 16% of CS/εL269F endplates (P < 0.05; n = 3
mice). Myofibrillar abnormalities in CS/εL269F endplates were
more prevalent than in controls, but were not statistically different from either nontransgenic (4.7% ± 2.3%; n = 3; P = 0.32) and CS
transgenic littermates (7.0% ± 4.1%; n = 4; P = 0.35). Moreover, there
was no statistical difference in myofibrillar abnormalities identified in CS-overexpressing mice compared with nontransgenic littermates. Thus, improvement of strength in CS/εL269F mice may
result, in addition, from factors distal to AChR activation, such as
an effect on muscle fiber contractile force.
CS does not prevent caspase activation at εL269F NMJs. Finally, to
investigate the cause of the persistent endplate myopathy, we
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the cleaved form of caspase-3 and compared sections of brachioradialis muscle biopsies from εL269F and CS/εL269F double transgenic mice (Figure 9, C and D, respectively). As with muscle from
patients, numerous muscle fibers were labeled in and around the
endplate region with active caspase-3 antibody. The number of
motor endplates labeled with active caspase-3 antibody was the
same in εL269F mice and CS/εL269F double-transgenic mice
(Figure 9E; 54% ± 5% vs. 51% ± 5%; n = 3; P = 0.59) and increased
roughly 4-fold when compared with that in nontransgenic littermates (54% ± 5% vs. 12% ± 4%; n = 3 mice; P < 0.05). No significant
difference was noted when comparing caspase-labeled endplates in
CS-overexpressing and nontransgenic mice (14% ± 4% vs. 12% ± 4%,
n = 3 mice, P = 0.76). Thus, inhibition of calpain or the presence of
overexpressed CS protein in SCS mice does not alter the extent of
caspase-3 activation.
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hypothesized that additional proteolytic processes remained active
in the presence of the CS transgene expression. Recently, we demonstrated that activated forms of the cysteine protease caspases
are present at the NMJ in muscle biopsies of SCS patients and in
εL269F mice (15, 16). Here we used the caspase fluorescent label
sulforhodamine-labeled VAD-FMK (SR-VAD-FMK) in acutely dissociated FDB muscle fibers to compare caspase enzymatic activity
in εL269F SCS and CS/εL269F mice (Figure 9, A and B, respectively). Numerous εL269F mouse muscle fibers reacted when SRVAD-FMK was used. Labeling was localized to the region of the
endplate in the area immediately surrounding the endplate, and
εL269F mice and double-transgenic CS/εL269F mice appeared
indistinguishable. To confirm that enzymatic activity correlated
with active caspase-3 protein, we employed antisera raised against
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A clearer understanding of how disturbed AChR channel gating
and leaky synaptic ion channels give rise to progressive impairment
of synaptic function in SCS will enhance our ability to understand
a variety of diseases in which synapse function is affected, including epilepsy and Alzheimer disease. In this study we have demonstrated that in intact, functioning synapses from mice expressing
mutant AChRs from SCS, the calcium-activated protease calpain is
activated and plays a role in promoting neuromuscular disease. The
increased calpain activity is dependent on the continued activity
of mutant AChRs and ceases after receptor blockade or axotomy,
coincident with the disappearance of accumulated calcium. Coexpression of a CS transgene in the εL269F mice partially corrects
strength and neuromuscular transmission, through a presynaptic
protective effect on synaptic size and strength, and to a lesser extent
focal myofibrillar degeneration. Features of the endplate myopathy,
such as nuclear and mitochondrial degeneration, persist despite
inhibition of calpain. These are associated with continued activation at the NMJ of a separate cascade of cysteine proteases whose
activity is not affected by CS (26, 27). These findings suggest that
CS improves neuromuscular transmission in εL269F mice predominantly by strengthening the synaptic contacts, rather than through
correcting the postsynaptic side of the NMJ. Calpain inhibition
may also provide some local protection of contractile apparatus.
The calcium-activated neutral protease calpain is a cysteine
protease of ubiquitous tissue distribution and broad subcellular
localization (28–30). In muscle, calpain is immunologically localized to endomysial collagen fibrils, basal lamina, sarcolemma,
Z bands, and NMJs, as well as the extracellular space (29, 31).
Calpains exist in multiple subtypes, differing in calcium sensitivity and function, and are involved in several cellular signaling
pathways, myoblast fusion, cytoskeletal protein turnover, neurite
outgrowth, and growth cone turning in development (26, 32–35).
In the neuromuscular system, during development and reinnervation, calpain and possibly other proteases play a prominent role in
synaptic remodeling and stabilization of neuromuscular contacts,
a process that is highly reminiscent of that observed in SCS (24, 25,
32, 36–39). Calpain activation may also contribute to the pathogenesis of stroke, myocardial infarction, Alzheimer disease, and
muscle disorders such as muscular dystrophy. mdx mice, which
bear mutations in the murine form of dystrophin, have a muscle
disease similar to Duchenne muscular dystrophy (40). mdx mice
bearing the same human CS transgene used in this study have less
severe dystrophic pathology (19).
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Elevated calpain activity in εL269F mice appears either as a diffuse increase or as intense regions of calpain activity located near the
NMJ. The focal activity of calpain is consistent with previous findings of histochemically detectable deposits of calcium at NMJs in
muscle biopsies from SCS patients or transgenic mice or localized
increases detected in SCS muscle in real time using calcium-sensitive
dyes in vitro (1, 9–11, 15, 16). The rapid disappearance of elevated calpain activity after axotomy or AChR blockade demonstrates that the
increased calpain activity is dynamic and directly related to ongoing
activity of mutant AChRs rather than to a compensatory response.
The improvement in strength and neuromuscular transmission
seen in εL269F transgenic mice expressing CS appears to result
predominantly from a strengthening of synaptic connections,
leading to normalized endplate size and MEPC frequency, rather
than a protective effect on AChRs. Rather than being increased,
both MEPC amplitude and AChR number were normal or slightly
reduced by overexpression of CS, although the slight effect on
MEPCs did not negatively affect the presynaptic improvement
in neuromuscular transmission. Reduced MEPC amplitudes and
AChR density in CS/εL269F mice may relate to the continued
activity of other proteases, such as the caspases, despite the expression of CS. Also, maintenance of synaptic contacts due to inhibition of nerve terminal retraction (see below) may protect compromised synaptic regions that would otherwise be eliminated and
increase the pool of smaller-amplitude MEPCs.

The increase in synaptic strength in SCS mice bearing the CS
transgene is consistent with the recognized participation of calcium-activated proteases in nerve terminal elimination of polyneuronal innervation, in stabilizing neuromuscular contacts, and in
remodeling of the NMJ. These processes are modulated by protease
inhibitors that appear to protect calpain targets in the muscle and
nerve cytoskeleton and basal lamina (22–25). Given the prominent
activity of calpain in mouse SCS muscle fibers, it is not surprising
that this enzyme participates in the NMJ remodeling recognized
in SCS. The current model expands on those of previous protease
inhibitor studies, as it involves a chronic, degenerative neuromuscular disease and direct transgenic targeting of calpastatin expression to muscle. Nevertheless, the same functional targets appear
to be protected. This is consistent with the observation in fusing
myoblasts that muscle-derived calpain is exteriorized and acts on
extracellular matrix components, such as fibronectin (33). Last, the
ultrastructural and immunoblot studies also point to some protection by calpain inhibition of myofibrillar structural proteins,
recognized targets of calpains, indicating the action and potential
role of this enzyme in muscle disease (41–43).
Calpain inhibition by CS expression did not improve several significant features of the endplate myopathy in SCS mice, including
degenerating nuclei and dilated mitochondria. A second family of
cysteine proteases, the caspase proteases, makes up a cascade of
enzymes that underlie apoptotic cell death mechanisms and are
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involved in a complex cross-talk with the calpains (44). Caspases
are also activated at the NMJ in SCS, and organellar degeneration
resolves in close parallel to the disappearance of caspase activity
after axotomy (15, 16). However, activated caspases persist at the
NMJ in SCS after calpain inhibition by CS (Figure 9). Studies have
pointed to a role for calpain itself in either the activation or inactivation of caspases in different settings (44, 45). CS is also a substrate for caspase-3, and its proteolysis by caspases in SCS might
be expected to allow for greater increases in calpain activation (44).
Our findings showing inhibition of calpain with overexpressed CS
demonstrate that calpain can be effectively inhibited while caspase-3
appears unaffected. These studies demonstrate that the calpain
and caspase protease systems play predominant roles in the pathogenesis of the SCS. Therapies designed to chronically reduce excessive calpain and caspase activities may be useful in the treatment
of the SCS and related excitotoxic and muscle disorders.
.FUIPET
Animals and reagents. The generation, characterization, and screening of
εL269F slow-channel transgenic mice (εL269F mice) and mice expressing
human CS has been reported previously (9, 19, 46). εL269F transgenic mice,
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line 14, express high levels, approximately 1,000-fold over endogenous WT
mouse ε subunit, of the mouse AChR ε subunit mRNA bearing an εL269F
mutation under the control of the muscle creatinine kinase promoter
(MCK). CS-transgenic mice, line 70.7, were derived from a construct that
expresses human CS under the control of the human β-actin promoter and
express CS protein at a level about 30-fold greater than endogenous protein. All breeding, screening, and experimental procedures were approved
by the Institutional Animal Care and Use Committee of the University of
Minnesota. Double-transgenic mice bearing both transgenes were detected
in F1 litters by PCR analysis of tail DNA using transgene-specific primers
and were viable. Control mice (WT) consisted of hybrid littermates or agematched transgene-negative mice. Age-matched mice, approximately 2–8
months, were used for all studies.
RαBT and BOC-Leu-Met-CMAC, (prepared as a 10-mM stock in DMSO)
were obtained from Molecular Probes (Invitrogen). SR-VAD-FMK was
acquired from BIOMOL International. N-acetyl-Leu-Leu-Nle-CHO (CP1)
was purchased from Calbiochem. Dulbecco’s modified Eagle’s medium
without phenol red (DMEM) and Hanks solution without phenol red
(Hanks) were from Invitrogen. Mouse monoclonal troponin-I (skeletal)
antibody was from Abcam. Rabbit polyclonal anti-Bax and goat polyclonal
troponin-I were purchased from Santa Cruz Biotechnology Inc. Secondary
antibodies conjugated to HRP and ECL reagents were from Amersham.
Anti-goat secondary antibody conjugated to HRP was purchased from
Jackson Immunoresearch Laboratories Inc. Nitrocellulose and PVDF
membranes were from Bio-Rad. Protease inhibitor cocktail Complete
Mini tablets (EDTA-free) were from Roche. BCA protein assay reagents
were from Pierce. All others were purchased from Sigma-Aldrich unless
otherwise specified.
Animals were sedated as needed for surgery using Avertin (250 mg/kg
i.p.) (47) and euthanized immediately after the surgery. Strength testing by
wire-hang test, measurement of AChR density by [125I]αBT binding, and
electromyography were performed as described previously (8, 9). Briefly, the
wire-hang test was performed by timing the period the animals were able
to hang suspended gripping a wire by their forepaws. AChR density was
determined as the ratio of [125I]αBT binding on labeled muscle bundles to
the number of endplates in the fibers. Electromyography was performed on
anesthetized animals by recording CMAPs using subcutaneous electrodes
placed over heel and at toe and evoked by direct stimulation of the sciatic
nerve. Voltage-clamp analysis was performed in excised diaphragm in vitro
using sharp electrodes inserted into individual muscle fibers, 1 for recording voltage and 1 for injecting current. The signals are amplified and digitized using a voltage-clamp amplifier and the software program pCLAMP
(Molecular Devices). Histochemical (tissue) stains for acetylcholinesterase
and GBHA were described previously (48, 49). Caspase-3 immunostaining
and microscopy were performed as previously described (16). Voltage-clamp
analyses of MEPCs were performed exactly as described previously (8).
Axotomy and AChR blockade. The left sciatic nerve was exposed through
a 5-mm incision in the upper thigh in anesthetized animals, and a 2-mm
portion was excised. Surgical incisions were closed with wound clips, and
animals were observed for recovery and normal food and water intake after
surgery. For αBT blockade of AChRs, the ventral hind paw was injected
subcutaneously alongside the FDB muscle with 10–25 μl of a solution
of 1.7 μM αBT in lactated Ringer’s solution (LR) (28-gauge needle) and
flushed out with LR after 20 minutes. FDB muscles were removed after 24
hours for calpain assay.
Muscle fiber dissociation and labeling. The hind-limb FDB muscles were
aseptically exposed and excised, and fibers were dissociated by incubation
in 400 μl digestion solution (3% collagenase, 1% hyaluronidase, and 5%
BSA in DMEM), at 37°C with 5% CO2 for 1.5 hours. To avoid muscle fiber
damage and contraction, all fiber suspensions were allowed to settle by
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gravity sedimentation in 0.7 ml PCR tubes for 20 minutes and the supernatants discarded. Controls consisted of contralateral dissociated FDB
muscle fiber suspensions incubated in 400 μl 80-μM CP1 or 1% DMSO
(vehicle) in DMEM at 37°C with 5% CO2 for 20 minutes.
Fiber bundles were transferred to a labeling cocktail consisting of 10
μM BOC-Leu-Met-CMAC, 0.3 μM RαBT, 1 μM ATP, and 5% horse serum
in Hanks solution without phenol red (Invitrogen), and, after removal of
tendinous material, triturated ×4 with a wide bore polyethylene plastic
pipette. The fiber suspensions were washed once in 700 μl Hanks prior to
mounting (in Hanks) on glass slides.
Staining with SR-VAD-FMK was performed after dissociation as
described above and according to the manufacturer’s instructions, except
that the fibers were washed extensively in a diffusion chamber overlaid
with a micromesh with Hanks prior to visualizing.
Western immunoblotting. FDB whole muscle or muscle fiber preparations
were disrupted in frosted glass homogenizers in 5 volumes of protein
extraction buffer thoroughly while on ice (20 mM phosphate buffer, pH
7.8, 10 mM EDTA, 10 mM EGTA, plus 1 tablet of protease inhibitor cocktail). Crude protein concentration was estimated using the BCA protein
assay, and samples were heat treated with standard loading buffer under
reducing conditions; loaded equally at 25 μg/well across all lanes; and electrophoresed on 10%–20% Bio-Rad Ready Gels. Sister gels were transferred
to either nitrocellulose (for goat and rabbit primaries) or PVDF (for mouse
primaries) membranes for 1 hour at 75 V. After blocking in 5% milk-TBS,
primary antibody dilutions were prepared in 5% milk-TBS and were 1:500
for goat anti–troponin-I, 1:5,000 for mouse monoclonal anti–troponin-I,
1:2,000 for rabbit polyclonal anti-Bax (data not shown). Monoclonal antiCS antibody (Takara Biomedicals) was used at 1:1,000. Secondary antibodies were prepared in 1% milk-TBS; the dilutions were 1:5,000 (or 1:10,000)
for anti-mouse and -rabbit and 1:10,000 for anti-goat. Membranes were
activated with ECL Chemiluminescence Detection System (Pierce Biotech)
or ChemiGlow (Alpha-InnoTec), according to the manufacturer’s instructions, and exposed to Kodak X-OMAT or Pierce CL-Xposure film. As a
loading control, a sister gel of the same homogenates was used to detect the
55-kDa species corresponding to IgG heavy chain (Figure 3F, upper panel).
Immunoblotting for CS was similar, except that tibialis anterior muscles
were homogenized in sample buffer containing 80 mM Tris-HCl (pH 6.8),
2% SDS, 10% glycerol, 100 mM DTT, and protease inhibitor cocktail, then
boiled and centrifuged at 15,000 g, and supernatants were subjected to 10%
PAGE. Because of the high levels of transgene expression compared with
endogenous mouse CS protein, εL269F single-transgenic and WT samples
were loaded at 40 μg/well, while εL269F/CS double-transgenic and CS single-transgenic samples were loaded at 4 μg/well. Ponceau red staining for
the actin band was used as loading control (Figure 3G, lower panel).
Microscopy and image analysis. Microscopy was performed immediately
after mounting, with a maximum latency of 1 hour. Images (72 dpi) were
collected utilizing an Olympus IX70 inverted microscope at ×10 power
equipped with a C4742-95 Hamamatsu digital camera head and analyzed
with imaging software (Metafluor; Universal Imaging Corp.). To visualize
BOC-Leu-Met-CMAC fluorescence, the fiber mounts were excited with a
UV lamp at 355 nm, and the 465-nm image emissions were collected for 70
1. Engel, A.G., et al. 1982. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion
channel. Ann. Neurol. 11:553–569.
2. Oosterhuis, H.J., et al. 1987. The slow channel syndrome. Two new cases. Brain. 110:1061–1079.
3. Gomez, C.M., et al. 1996. A beta-subunit mutation in the acetylcholine receptor channel gate
causes severe slow-channel syndrome. Ann. Neurol.
39:712–723.

ms with a standard DAPI filter cube. For RαBT visualization of the AChRs
found at the endplates, fibers were excited at 528.7 nm, and emissions were
collected at 550 nm for 300 ms using a standard rhodamine band pass
filter set. Forty to 60 intact fibers identified by systematic scanning were
recorded per experimental group. For each fiber, the area corresponding
to the endplate region (as localized with RαBT) was marked by placement
of a circle on the image with a diameter matching that of the fiber. The
average fluorescence intensity for BOC-Leu-Met-CMAC in this area was
recorded using an image analysis program (Metafluor) and exported to
a spreadsheet file (Excel; Microsoft) for statistical analysis. Endplate (as
determined by RαBT staining) cross-sectional area was estimated utilizing
a ×10 objective and Hamamatsu camera capturing 72-dpi images, in which
the measure tool in the image processing program, Photoshop (Adobe),
detected a pixel width of 2.7 μm for such images, which when squared was
7.3 μm2. Therefore, the total number of pixels captured by Metafluor at the
threshold divided by 7.3 was reported as the cross-sectional area.
For SR-VAD-FMK visualization, the images were first recorded under
visual light illumination with Metafluor for 50 ms through a ×40 oil immersion objective. Immediately afterward, the same field of view was excited at
528.7 nm, and 550-nm emissions were recorded through a standard rhodamine band pass filter set. For display, merged montages of the Metafluor
images were prepared using a graphics program (Photoshop; Adobe).
Statistics. For comparison of 2 groups, data were compared using 2-tailed
Student’s t test when assuming unequal variances. For comparison of 3 or
more groups, data were analyzed using ANOVA followed by Bonferroni
and Dunn’s post-hoc analysis. Data are reported as mean ± SEM. Overall
experimental significance was assigned for individual comparisons when
P was less than 0.0083, with a 95% confidence level (overall experimental
significance, P < 0.05). A contralateral comparison strategy was applied
where applicable, so one could compare treated and untreated sides within
the same animal to eliminate concerns of individual genetic variation.

Note added in proof. Chen et al. recently reported that calpain, activated by cholinergic stimulation and inhibited by rapsyn, drives
CDK5 activity, which disperses AChR clusters in developing muscle fibers (50). This finding identifies additional NMJ proteins that
may be involved in SCS pathogenesis.
"DLOPXMFEHNFOUT
We gratefully acknowledge Holly Kordasciewicz and Mark Rich
for many useful discussions during the course of this project. This
work was funded by a grant from the Muscular Dystrophy Association and by NIH grant R01-NS033202.
Received for publication September 18, 2006, and accepted in
revised form June 26, 2007.
Address correspondence to: Christopher M. Gomez, The University
of Chicago, Department of Neurology, 5841 S. Maryland Avenue,
MC 2030, Chicago, Illinois 60637, USA. Phone: (772) 702-6390;
Fax: (773) 702-5670; E-mail: gomez001@uchicago.edu.

4. Milone, M., et al. 1997. Slow-channel myasthenic
syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable
to mutation in the m2 domain of the acetylcholine
receptor alpha subunit. J. Neurosci. 17:5651–5665.
5. Engel, A.G., et al. 1996. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum. Mol. Genet. 5:1217–1227.
6. Ohno, K., et al. 1995. Molecular genetic basis of

The Journal of Clinical Investigation

http://www.jci.org

Volume 117

a slow channel myasthenic syndrome [abstract].
Muscle Nerve. 18:463.
7. Sine, S.M., et al. 1995. Mutation of the acetylcholine receptor a subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding
affinity. Neuron. 15:229–239.
8. Gomez, C.M., et al. 1996. A transgenic mouse
model of the slow-channel syndrome. Muscle Nerve.
19:79–87.
9. Gomez, C.M., et al. 1997. Slow-channel transgenic

Number 10

October 2007



Downloaded on August 12, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/30383

SFTFBSDIBSUJDMF
mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. J. Neurosci.
17:4170–4179.
10. Gomez, C.M., et al. 2002. Active calcium accumulation underlies severe weakness in a panel of mice with
slow-channel syndrome. J. Neurosci. 22:6447–6457.
11. Li, M., et al. 2000. Functional role of caspase-1 and
caspase-3 in an ALS transgenic mouse model. Science. 288:335–339.
12. Felderhoff-Mueser, U., et al. 2002. Pathways leading to apoptotic neurodegeneration following
trauma to the developing rat brain. Neurobiol. Dis.
11:231–245.
13. Bizat, N., et al. 2003. Calpain is a major cell death
effector in selective striatal degeneration induced
in vivo by 3-nitropropionate: implications for Huntington’s disease. J. Neurosci. 23:5020–5030.
14. Vohra, B.P., et al. 2004. Focal caspase activation
underlies the endplate myopathy in slow-channel
syndrome. Ann. Neurol. 55:347–352.
15. Vohra, B.P.S., et al. 2006. Activation of apoptotic
pathways at muscle fiber synapses is circumscribed
and reversible in a slow channel syndrome model.
Neurobiol. Dis. 23:462–470.
16. Rosser, B.G., Powers, S.P., and Gores, G.J. 1993.
Calpain activity increases in hepatocytes following
addition of ATP. Demonstration by a novel fluorescent approach. J. Biol. Chem. 268:23593–23600.
17. Zayas, R., Groshong, J.S., and Gomez, C.M. 2007.
Inositol-1,4,5-triphosphate receptors mediate activity-induced synaptic Ca2+ signals in muscle fibers
and Ca2+ overload in slow-channel syndrome. Cell
Calcium. 41:343–352.
18. Akaaboune, M., Culican, S.M., Turney, S.G., and
Lichtman, J.W. 1999. Rapid and reversible effects of
activity on acetylcholine receptor density at the neuromuscular junction in vivo. Science. 286:503–507.
19. Spencer, M.J., and Mellgren, R.L. 2002. Overexpression of a calpastatin transgene in mdx muscle
reduces dystrophic pathology. Hum. Mol. Genet.
11:2645–2655.
20. Oh, S.J., Head, T., Fesenmeier, J., and Claussen, G.
1995. Peroneal nerve repetitive nerve stimulation
test: its value in diagnosis of myasthenia gravis
and Lambert-Eaton myasthenic syndrome. Muscle
Nerve. 18:867–873.
21. Magleby, K.L. 2004. Neuromuscular transmission.
In Myology. 3rd edition. A.G. Engel and C. Franzini
Armstrong, editors. McGraw-Hill. New York, New
York, USA. 383–388.
22. O’Brien, R.A., Ostberg, A.J., and Vrbova, G. 1984.
Protease inhibitors reduce the loss of nerve terminals



induced by activity and calcium in developing rat
soleus muscles in vitro. Neuroscience. 12:637–646.
23. Vrbova, G., and Fisher, T.J. 1989. The effect of
inhibiting the calcium activated neutral protease,
on motor unit size after partial denervation of the
rat soleus muscle. Eur. J. Neurosci. 1:616–625.
24. Connold, A.L., and Vrbova, G. 1994. Neuromuscular contacts of expanded motor units in rat soleus
muscles are rescued by leupeptin. Neuroscience.
63:327–338.
25. Tyc, F., and Vrbova, G. 1995. Stabilisation of neuromuscular junctions by leupeptin increases motor
unit size in partially denervated rat muscles. Brain
Res. Dev. Brain Res. 88:186–193.
26. Chan, S.L., and Mattson, M.P. 1999. Caspase and
calpain substrates: roles in synaptic plasticity and
cell death. J. Neurosci. Res. 58:167–190.
27. Wang, K.K. 2000. Calpain and caspase: can you tell
the difference? Trends Neurosci. 23:20–26.
28. Yoshimura, N., et al. 1986. Immunogold electronmicroscopic localisation of calpain I in skeletal
muscle of rats. Cell Tissue Res. 244:265–270.
29. Badalamente, M.A., Hurst, L.C., and Stracher, A.
1987. Localization and inhibition of calciumactivated neutral protease (CANP) in primate
skeletal muscle and peripheral nerve. Exp. Neurol.
98:357–369.
30. Goll, D.E., Thompson, V.F., Li, H., Wei, W., and
Cong, J. 2003. The calpain system. Physiol. Rev.
83:731–801.
31. Kumamoto, T., et al. 1992. Localization of the
Ca(2+)-dependent proteinases and their inhibitor in normal, fasted, and denervated rat skeletal
muscle. Anat. Rec. 232:60–77.
32. Shea, T.B., Cressman, C.M., Spencer, M.J., Beermann, M.L., and Nixon, R.A. 1995. Enhancement
of neurite outgrowth following calpain inhibition is mediated by protein kinase C. J. Neurochem.
65:517–527.
33. Dourdin, N., et al. 1997. Myoblast fusion requires
fibronectin degradation by exteriorized m-calpain.
Exp. Cell Res. 235:385–394.
34. Ohbayashi, K., Fukura, H., Inoue, H.K., Komiya, Y.,
and Igarashi, M. 1998. Stimulation of L-type Ca2+
channel in growth cones activates two independent
signaling pathways. J. Neurosci. Res. 51:682–696.
35. Robles, E., Huttenlocher, A., and Gomez, T.M. 2003.
Filopodial calcium transients regulate growth cone
motility and guidance through local activation of
calpain. Neuron. 38:597–609.
36. Song, D.K., Malmstrom, T., Kater, S.B., and Mykles,
D.L. 1994. Calpain inhibitors block Ca(2+)-induced

The Journal of Clinical Investigation

http://www.jci.org

Volume 117

suppression of neurite outgrowth in isolated
hippocampal pyramidal neurons. J. Neurosci. Res.
39:474–481.
37. Gomez, C.M., et al. 1996. A beta-subunit mutation in the acetylcholine receptor channel gate
causes severe slow-channel syndrome. Ann. Neurol.
39:712–723.
38. Harding, D.I., Greensmith, L., and Vrbova, G. 1999.
Stabilizing neuromuscular contacts reduces motoneuron death caused by paralysis of muscles in
neonatal rats. Neuroscience. 93:1141–1146.
39. Simpkins, K.L., et al. 2003. Selective activation
induced cleavage of the NR2B subunit by calpain.
J. Neurosci. 23:11322–11331.
40. Cavanna, J.S., et al. 1988. Molecular and genetic mapping of the mouse mdx locus. Genomics. 3:337–341.
41. Beckerle, M.C., Burridge, K., DeMartino, G.N., and
Croall, D.E. 1987. Colocalization of calcium-dependent protease II and one of its substrates at sites of
cell adhesion. Cell. 51:569–577.
42. Gao, W.D., et al. 1997. Role of troponin I proteolysis
in the pathogenesis of stunned myocardium. Circ.
Res. 80:393–399.
43. Barta, J., et al. 2003. Calpain-1-dependent degradation of troponin I mutants found in familial
hypertrophic cardiomyopathy. Mol. Cell. Biochem.
251:83–88.
44. Neumar, R.W., Xu, Y.A., Gada, H., Guttmann, R.P.,
and Siman, R. 2003. Crosstalk between calpain and
caspase proteolytic systems during neuronal apoptosis. J. Biol. Chem. 278:14162–14167.
45. Chua, B.T., Guo, K., and Li, P. 2000. Direct cleavage by the calcium-activated protease calpain
can lead to inactivation of caspases. J. Biol. Chem.
275:5131–5135.
46. Tidball, J.G., and Spencer, M.J. 2002. Expression of
a calpastatin transgene slows muscle wasting and
obviates changes in myosin isoform expression during murine muscle disuse. J. Physiol. 545:819–828.
47. Papaioannou, V.E., and Fox, J.G. 1993. Efficacy of
tribromoethanol anesthesia in mice. Lab. Anim. Sci.
43:189–192.
48. Kashiwa, H.K. 1970. Calcium phosphate in osteogenic cells. A critique of the glyoxal bis(2-hydroxyanil) and the dilute silver acetate methods. Clin.
Orthop. Relat. Res. 70:200–211.
49. Namba, T., and Grob, D. 1970. Cholinesterase activity of motor end plate in human skeletal muscle.
J. Clin. Invest. 49:936–942.
50.Chen, F., et al. 2007. Rapsyn interaction with calpain
stabilizes AChR clusters at the neuromuscular
junction. Neuron. 55:247–260.

Number 10

October 2007

